Novozymes A/S (OTCMKTS:NVZMY – Get Free Report) was the target of a significant drop in short interest in July. As of July 31st, there was short interest totaling 3,603 shares, a drop of 86.4% from the July 15th total of 26,584 shares. Approximately 0.0% of the company’s stock are sold short. Based on an average daily trading volume, of 47,927 shares, the days-to-cover ratio is currently 0.1 days.
Analyst Ratings Changes
A number of research firms have weighed in on NVZMY. Zacks Research raised Novozymes A/S from a “strong sell” rating to a “hold” rating in a research report on Monday, June 8th. Kepler Capital Markets raised shares of Novozymes A/S from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, May 13th. Two analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, Novozymes A/S presently has an average rating of “Buy”.
Read Our Latest Report on Novozymes A/S
Novozymes A/S Stock Performance
About Novozymes A/S
Novozymes A/S is a Danish biotechnology company that develops, produces and markets industrial enzymes and microorganisms. Headquartered in Bagsværd, Denmark, the company focuses on using biological solutions to improve industrial processes across a range of end markets. Its offerings are designed to increase product performance or process efficiency while reducing energy, water and chemical consumption for customers.
The company’s product portfolio includes enzymes and microbial solutions for household care (detergents and cleaning products), food and beverages (baking, brewing and dairy applications), bioenergy (enzymes for biofuel production), agriculture (microbial crop inputs and biocontrols) and industrial processing (textiles, pulp and paper, and wastewater treatment).
See Also
- Five stocks we like better than Novozymes A/S
- Fastly’s Q2 Rally Shows Investors Are Buying the Edge AI Turnaround
- Paramount’s 30-Film Promise Puts AMC Back in the Box Office Conversation
- DraftKings’ Predictions Push Could Be the Bet That Matters Most
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
Receive News & Ratings for Novozymes A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novozymes A/S and related companies with MarketBeat.com's FREE daily email newsletter.
